First monoclonal antibody approved using the Animal Efficacy Rule

FDA approves raxibacumab to treat inhalational anthrax

 

Silver Spring (December 14, 2012) – The U.S. Food and Drug Administration today approved raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

 

Raxibacumab is a monoclonal antibody that neutralizes toxins produced by B. anthracis that can cause massive and irreversible tissue injury and death. A monoclonal antibody is a protein that closely resembles a human antibody that identifies and neutralizes foreign material like bacteria and viruses. Anthrax is a potential biological terrorism threat because the spores are resistant to destruction and can be easily spread by release in the air.

 

The FDA granted raxibacumab fast track designation, priority review, and orphan product designation. The drug demonstrated the potential to fill an unmet medical need, has the potential to provide safe and effective treatment where no satisfactory alternative therapy exists, and is intended to treat a rare disease, respectively.

 

Raxibacumab is the first monoclonal antibody approved under the FDA’s Animal Efficacy Rule, which allows efficacy findings from adequate and well-controlled animal studies to support FDA approval when it is not feasible or ethical to conduct trials in humans. In this case, because inhalational anthrax is a rare and lethal disease, it is not possible to conduct adequate efficacy trials in humans.

 

“In addition to antibiotics, raxibacumab will be a useful treatment to have available should an anthrax bioterrorism event occur,” said Edward Cox, M.D., M.P.H, director of the Office of Antimicrobial Products in FDA’s Center for Drug Evaluation and Research. “Although antibiotics are approved to prevent and treat anthrax infection, raxibacumab is the first approved agent that acts by neutralizing the toxins produced by B. anthracis.”

 

Raxibacumab’s effectiveness for inhalational anthrax was demonstrated in one study in monkeys and three studies in rabbits. All animals were administered aerosolized B. anthracis spores, and efficacy was determined by survival at the end of the studies. Animals received varying doses of raxibacumab, placebo or antibiotics normally used to treat anthrax.

 

More animals treated with raxibacumab lived compared to animals treated with placebo. Sixty-four percent of animals in the monkey study and 44 percent of animals in one rabbit study receiving the 40 milligrams per kilogram dose of raxibacumab survived exposure to anthrax, compared with none in the placebo groups. All surviving animals developed toxin-neutralizing antibodies. Another study in rabbits showed that 82 percent of animals treated with antibiotics and raxibacumab survived exposure to anthrax compared with 65 percent of animals receiving antibiotic treatment alone.

 

The safety of raxibacumab was evaluated in 326 healthy human volunteers. Common side effects included rash, extremity pain, itching and drowsiness.

 

Raxibacumab was developed by Rockville, Md.-based Human Genome Sciences, in conjunction with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority. Human Genome Sciences has since been acquired by GlaxoSmithKline.

 

 

For more information

 

 

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

 

 


U.S. Food and Drug Administration (FDA), 14.12.2012 (hB).

MEDICAL NEWS

New guidance to prevent the tragedy of unrecognized esophageal intubation
Overly restrictive salt intake may worsen outcomes for common form…
COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Scientists discover how salt in tumours could help diagnose and…

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Kaltplasma bei diabetischem Fußsyndrom wirkt via Wachstumsfaktoren
Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…
Suliqua®: In komplexem Umfeld – einfach besser eingestellt
Suliqua®: Überlegene HbA1c-Senkung  im Vergleich zu Mischinsulinanalogon
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…

ERNÄHRUNG

Gesunde Ernährung: „Nicht das Salz und nicht das Fett verteufeln“
Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?

ONKOLOGIE

Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
Aktuelle Kongressdaten zum metastasierten Mammakarzinom und kolorektalen Karzinom sowie Neues…
Mehr Lebensqualität für onkologische Patient:innen durch bessere Versorgung: Supportivtherapie, Präzisionsonkologie,…
WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver

MULTIPLE SKLEROSE

Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…